Global Hospital Acquired Disease Testing Market Report and Forecast 2024-2032

Global Hospital Acquired Disease Testing Market Outlook 

The global hospital acquired disease testing market attained a value of USD 1609.43 million in 2023. The market is further anticipated to reach USD 6312.63 million by 2032 while registering a CAGR of 16.4% over the forecast period of 2024-2032.

On the basis of the indication, the urinary tract infection segment is estimated to be the largest indication segment. The segment growth is primarily attributed to the rising incidences of immune suppression accompanied by urologic abnormality due to the consumption of unhealthy food, alcohol, and smoking.

Regionally, North America is anticipated to dominate the market in 2020, owing to the increasing reimbursement policies and favourable government initiatives towards hospital acquired (nosocomial) infections.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Properties and Applications 

A hospital acquired infection (HAI) or diseases or nosocomial infection is an infection which is acquired from the hospital or the clinical surrounding including nursing homes, and rehabilitation centres, among others. The incubation period of the nosocomial infection generally varies between 48 hours to 4 days. The prime reason behind the cause of HAI is the lack of proper hygiene in the hospital or clinical environment by the internal staff. Also, other factors that can be attributed to the growth of HAI include below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the commonly occurring nosocomial infections include pneumonia, urinary tract infections (UTI), and primary bloodstream infections. 

On the basis of indication, the market is segmented into:

• UTI (Urinary Tract Infection)
• SSI (Surgical Site Infection)
• Pneumonia
• Bloodstream Infections
• MRSA (Methicillin-Resistant Staphylococcus Aureus)
• Others

The EMR report looks into the regional markets of hospital acquired disease testing like Europe, the Asia Pacific, North America, Latin America, and the Middle East and Africa.

Market Analysis 

With the increasing global population, rapid urbanisation, and modernisation of healthcare infrastructure, there has been a significant increase in the number of health care facilities. This has led to the rising incidence of HAIs, which, in turn, is propelling the demand for hospital acquired disease tests. The rising adoption of advanced technologies for preventing, diagnosing, and monitoring HAIs, such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridisation, is further expected to augment the market growth.

Moreover, the growing awareness of HAIs among patients and stringent government regulations to penalize hospitals with a high incidence of HAIs are some of the other factors that are strengthening the growth of the market. Increasing research and development activities for developing new techniques, coupled with various mergers and acquisitions and strategic partnerships by various manufacturers, are expected to create potential revenue opportunities for players operating in the market over the forecast period.

Competitive Landscape 

The report presents a detailed analysis of the following key players in the global hospital acquired disease testing market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Abbott Laboratories
• Becton, Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Siemens Healthcare GmbH
• Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter's Five Forces model.

Key Highlights of the Report